Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KI-3142
- Development stage
- Preclinical
- Lead developer
- Kuhnil Pharmaceutical
- Modality
- Small Molecules
01
Overview
KI-3142 is an investigational small molecule therapeutic candidate being developed by the South Korean company Kuhnil Pharmaceuticals. It is specifically targeted for the treatment of ovarian cancer and is part of the company's internal "KI" series of research projects. Currently, the drug is in the early stages of development, primarily categorized as being in the research or preclinical phase. As a small molecule oncology candidate, KI-3142 represents Kuhnil's efforts to expand its portfolio into targeted cancer therapies, although specific details regarding its molecular target, pharmacological profile, and precise mechanism of action remain proprietary and have not been publicly disclosed in clinical databases.
Beyond the preview
Go deeper on KI-3142.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KI-3142.